| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 9e-05 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.2 | 0.0006 |